Hematologic and coagulation studies were carried out during 12 heparin-free hemodialysis in 9 maintenance hemodialysis patients. Treatment employed a C-DAK 4000 cellulose acetate membrane hemodialyzer. Both hemodialyzer and blood tubing were periodically flushed with physiologic saline. No significant clotting of the hemodialyzers was encountered in uneventful dialyses. Platelet counts, platelet aggregation with ADP and epinephrine, antithrombin III and fibrinogen/fibrin degradation products were not significantly changed compared with pre-dialysis values. Fibrino-peptide A levels, elevated pre-treatment, demonstrated additional rise during dialysis. These findings support clinical experience that this anticoagulation-free method can be used safely and effectively to dialyze patients at risk for bleeding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000182924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemodialysis without Systemic Anticoagulation: A Randomized Controlled Trial to Evaluate Five Strategies in Patients at a High Risk of Bleeding.
Med Sci (Basel)
August 2024
Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia.
Article Synopsis
- A study aimed to evaluate the effectiveness of various heparin-free hemodialysis treatments compared to standard intermittent flushes in preventing clotting and minimizing interruptions during dialysis sessions.
- Conducted as an open-label randomized controlled trial, 40 chronic hemodialysis patients participated and were divided into five treatment groups to assess different strategies over three sessions.
- Results indicated that the combination of heparin-coated dialyzers with intermittent flushes showed the highest success (100%), while other groups had variable success rates, with one group showing as low as 38%, suggesting potential for combining interventions to enhance hemodialysis procedures for patients contraindicated for heparin use.
Toward acid- and heparin-free dialysis: the regional anticoagulation approach.
Clin Kidney J
August 2024
Centre of Nephrology and Renal Transplantation, Hôpital de la Conception, CHU de Marseille, Marseille, France.
Background: In chronic intermittent hemodialysis, heparin is the standard anticoagulant as is the use of acid-containing dialysate. Regional anticoagulation (RA) with a calcium-free, citrate-containing dialysate has been developed. We compared RA using a calcium-free, citrate-free dialysate, routinely used in our center, versus systemic heparinization.
View Article and Find Full Text PDFSafety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial.
Commun Med (Lond)
July 2024
Aronora, Inc., Portland, OR, USA.
Background: The protein C system regulates blood coagulation, inflammation, and vascular integrity. AB002 is an injectable protein C activating enzyme under investigation to safely prevent and treat thrombosis. In preclinical models, AB002 is antithrombotic, cytoprotective, and anti-inflammatory.
View Article and Find Full Text PDFA randomized crossover trial of regional anticoagulation modalities for intermittent hemodialysis.
Nephrol Dial Transplant
July 2024
Département de Néphrologie et Transplantation d'organes, French Intensive Care Renal Network, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Introduction: The optimal regional anticoagulation (RA) of dialysis filters in patients at risk of bleeding remains elusive. Inducing hypocalcemia within the filter by using a calcium-free dialysate has emerged as an easy-to-use heparin-free RA, including in critically ill patients, but comparative studies are lacking.
Methods: We conducted a multicentre, randomized, crossover trial to compare the efficacy and tolerance of two RAs (heparin-coated membrane (HCM) or calcium free dialysate with calcium reinjection according to ionic dialysance (CFD)) in patients requiring hemodialysis and at risk of bleeding.
Calcium-Free Dialysate Hemodialysis: A Simplified Approach.
J Pers Med
June 2024
Nephrology, Haemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, 38043 Grenoble, France.
Intermittent hemodialysis (HD) in high-bleeding-risk patients presents a challenge as circuit anticoagulation using heparin is contraindicated in such cases. Recently, the use of calcium-free citrate-containing dialysate with calcium supplementation emerged as a viable alternative to heparin-circuit anticoagulation. This is a retrospective, monocentric study to evaluate dialysis efficacy using calcium-free citrate-containing dialysate with calcium reinjection into the venous line in hemodialysis patients at risk of bleeding.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!